HL7 launches payer group to help with interoperability

Laura Pedulli | | Health Exec | Precision Medicine

 

Health Level Seven (HL7) International has launched a payer user group to help promote interoperability standards within that segment of the healthcare industry.

The user group will support members of the payer community utilizing HL7 standards to better manage member care, promote better medical outcomes and support a more sustainable and affordable healthcare system, according to a release.

The group will focus on the following areas:

  • Educating and training the payer community on how to implement HL7
  • Sharing lessons learned during implementations
  • Providing feedback to HL7 workgroups responsible for the creation of the standards that impact the payer community
  • Being a collaborative resource for other stakeholders at HL7 for payer perspectives

“We believe that this program will drive highly valued collaboration and lead to more effective implementations of HL7 standards. We anticipate continued organic growth of user groups, with increasing demand from other stakeholder communities,” said Charles Jaffe, MD, PhD, and CEO of HL7.

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.